Telik, Inc. (TELK) - Financial and Strategic SWOT Analysis Review

GlobalData
June 4, 2014
41 Pages - SKU: GBDT5268592
Telik, Inc. (TELK) - Financial and Strategic SWOT Analysis Review

provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Telik, Inc. (Telik) is a development stage bio pharmaceutical company. It carries out discovery, development and commercialization of novel small molecule drugs for the treatment of cancer and other major diseases. The company's research and development activities are focused on advancing its two most clinical advanced drug candidates, Telintra and Telcyta. Telintra is now at phase II clinical development stage, using for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia.

Telik, Inc. Key Recent Developments

May 15, 2014: Telik Announces First Quarter 2014 Financial Results
Mar 10, 2014: Telik Announces Fourth Quarter And 2013 Year End Financial Results
Nov 12, 2013: Telik Announces Third Quarter 2013 Financial Results
Aug 09, 2013: Telik Announces Second Quarter 2013 Financial Results
May 10, 2013: Telik Reports Q1 2013 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Additional Information



Country

United States

More Pharmaceuticals Company reports by GlobalData

Sun Pharmaceutical Industries Limited (SUNPHARMA) - Financial and Strategic SWOT Analysis Review by GlobalData
Sun Pharmaceutical Industries Limited (SUNPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. ...
SkyePharma PLC (SKP) - Financial and Strategic SWOT Analysis Review by GlobalData
SkyePharma PLC (SKP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile ...
Medicamen Biotech Ltd. (531146) - Financial and Strategic SWOT Analysis Review by GlobalData
Medicamen Biotech Ltd. (531146) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The ...
Lincoln Pharmaceuticals Ltd (531633) - Financial and Strategic SWOT Analysis Review by GlobalData
Lincoln Pharmaceuticals Ltd (531633) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 125  
    Site License  USD 250  
    Global Site License  USD 375  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!